These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22008853)

  • 41. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical development of MEK inhibitors.
    Zhao Y; Adjei AA
    Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK.
    Lu T; Zou Y; Xu G; Potter JA; Taylor GL; Duan Q; Yang Q; Xiong H; Qiu H; Ye D; Zhang P; Yu S; Yuan X; Zhu F; Wang Y; Xiong H
    Oncotarget; 2016 Dec; 7(50):83017-83030. PubMed ID: 27806324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. U0126, a mitogen-activated protein kinase kinase 1 and 2 (MEK1 and 2) inhibitor, selectively up-regulates main isoforms of CYP3A subfamily via a pregnane X receptor (PXR) in HepG2 cells.
    Smutny T; Bitman M; Urban M; Dubecka M; Vrzal R; Dvorak Z; Pavek P
    Arch Toxicol; 2014 Dec; 88(12):2243-59. PubMed ID: 24819614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel MEK1/2 inhibitor induces G1/S cell cycle arrest in human fibrosarcoma cells.
    Matsui TA; Murata H; Sowa Y; Sakabe T; Koto K; Horie N; Tsuji Y; Sakai T; Kubo T
    Oncol Rep; 2010 Aug; 24(2):329-33. PubMed ID: 20596617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
    Kurian N; Cohen TS; Öberg L; De Zan E; Skogberg G; Vollmer S; Baturcam E; Svanberg P; Bonn B; Smith PD; Vaarala O; Cunoosamy DM
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2611-2624. PubMed ID: 32063702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Off-target effects of MEK inhibitors.
    Wauson EM; Guerra ML; Barylko B; Albanesi JP; Cobb MH
    Biochemistry; 2013 Aug; 52(31):5164-6. PubMed ID: 23848362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
    Xie X; Zu X; Liu F; Wang T; Wang X; Chen H; Liu K; Wang P; Liu F; Zheng Y; Bode AM; Dong Z; Kim DJ
    Mol Carcinog; 2019 Jul; 58(7):1248-1259. PubMed ID: 31100197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor.
    Yamaguchi T; Yoshida T; Kurachi R; Kakegawa J; Hori Y; Nanayama T; Hayakawa K; Abe H; Takagi K; Matsuzaki Y; Koyama M; Yogosawa S; Sowa Y; Yamori T; Tajima N; Sakai T
    Cancer Sci; 2007 Nov; 98(11):1809-16. PubMed ID: 17784872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
    Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
    Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Therapeutic Potential of MEK1/2 Inhibitors in the Treatment of Gynecological Cancers: Rational Strategies and Recent Progress.
    Ghanaatgar-Kasbi S; Khazaei M; Rastgar-Moghadam A; Ferns GA; Hassanian SM; Avan A
    Curr Cancer Drug Targets; 2020; 20(6):417-428. PubMed ID: 32329688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
    Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
    Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
    Paternot S; Roger PP
    Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY; Shin SJ; Kim HS
    Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
    Mandal R; Becker S; Strebhardt K
    Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors.
    Auld DS; Davis CA; Jimenez M; Knight S; Orme JP
    Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.